Temozolomide Plus Vorinostat in Relapse/Refractory Acute Myeloid Leukemia (AML)

Trial ID or NCT#



not recruiting iconNOT RECRUITING


The purpose of the study is to first determine if temozolomide plus vorinostat in combination can control relapsed or refractory acute myeloid leukemia (AML) and determine if this combination can be safely taken. The study will look at the side effects of the Temozolomide plus Vorinostat in combination and whether the treatment schedule is tolerated.

Official Title

Temozolomide Plus Vorinostat in Patients With Relapse/Refractory Acute Myeloid Leukemia (AML)

Eligibility Criteria

Ages Eligible for Study: Older than 18 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No


Jason Gotlib
Hematologist, Medical oncologist, Leukemia specialist, Hematologist-Oncologist
Professor of Medicine (Hematology)

Contact us to find out if this trial is right for you.


Jack Taw